October 2022 in “Journal of Armed Forces Medical College, Bangladesh” In this clinical trial, Tofacitinib effectively promoted hair regrowth in patients with alopecia areata, alopecia totalis, and alopecia universalis, with 75.6% experiencing no side effects, making it a promising treatment option according to the study.
September 2022 in “Journal of the American Academy of Dermatology” This study observed that tofacitinib therapy over about 16 weeks had a positive effect in children with alopecia areata, reducing the SALT index significantly in some patients.
August 2022 in “Dermatology Online Journal” Oral and topical tofacitinib can effectively treat severe hair loss with minimal side effects.
1 citations
,
October 2020 in “Journal of Cosmetic Dermatology” This study presents a case of treatment-resistant alopecia universalis that successfully responded to a combination of tofacitinib and oral minoxidil, highlighting a potential therapeutic approach for challenging cases of alopecia areata.
4 citations
,
July 2018 in “PubMed” This study reports significant hair regrowth in 11 patients with severe alopecia areata following longstanding treatment with oral tofacitinib and also highlights successful treatment using topical tofacitinib cream in one case.
49 citations
,
May 2018 in “Journal of the American Academy of Dermatology” This letter discusses the limited treatment options for pediatric alopecia areata and the lack of controlled studies for therapies like systemic and off-label immunosuppressive drugs, without reporting new clinical results.
24 citations
,
June 2016 in “Acta dermato-venereologica” In this case report, tofacitinib was associated with new hair growth on psoriasis lesions after three months of treatment.